Tucatinib
- Generic Name
- Tucatinib
- Brand Names
- Tukysa
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24N8O2
- CAS Number
- 937263-43-9
- Unique Ingredient Identifier
- 234248D0HH
- Background
Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other ch...
- Indication
本品与曲妥珠单抗和卡培他滨联用治疗人类表皮生长因子受体2(HER2)阳性且已出现转移(如脑转移)或无法进行乳房切除术的乳腺癌成人患者，患者应接受过一种或多种抗HER2乳腺癌药物治疗。
- Associated Conditions
- Breast Cancer, Unresectable Breast Cancer, Wild-type RAS Metastatic Colorectal Cancer, Unresectable RAS Wild Type Colorectal Cancer
- Associated Therapies
- -
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT06686394
The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 72
- Registration Number
- NCT06439693
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06162559
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT06157892
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Other, Italy
🇺🇸Arizona Cancer Center / University of Arizona, Tucson, Arizona, United States
🇺🇸Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California, United States
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Jonathan Riess
- Target Recruit Count
- 36
- Registration Number
- NCT06067776
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT05892068
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Conditions
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 54
- Registration Number
- NCT05868226
- Locations
- 🇺🇸
The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois, United States
Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05748834
- Locations
- 🇺🇸
Alliance Cancer Specialists, Bensalem, Pennsylvania, United States
🇺🇸Maryland Oncology Hematology, Columbia, Maryland, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
- Conditions
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05673928
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT05672524
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.